Kandai Nozu, Mayumi Sako, Seiji Tanaka, Yuji Kano, Yoko Ohwada, Tamaki Morohashi, Riku Hamada, Yasufumi Ohtsuka, Masafumi Oka, Koichi Kamei, Aya Inaba, Shuichi Ito, Tomoyuki Sakai, Hiroshi Kaito, Yuko Shima, Kenji Ishikura, Hidefumi Nakamura, Koichi Nakanishi, Tomoko Horinouchi, Akihide Konishi, Takashi Omori, Kazumoto Iijima
BACKGROUND: Only 80% of children with idiopathic nephrotic syndrome respond well to glucocorticoid therapy. Multidrug-resistant nephrotic syndrome (MRNS) is associated with a poor kidney prognosis. Several retrospective studies have identified rituximab as an effective treatment for MRNS; however, prospective studies are required to assess its efficacy and safety. METHODS: We conducted a multicenter, non-blinded, single-arm trial to investigate the efficacy and safety of rituximab in patients with childhood-onset MRNS who were resistant to cyclosporine and more than three courses of steroid pulse therapy...
November 27, 2023: Clinical and Experimental Nephrology